Farris Alton B, van der Laak Jeroen, van Midden Dominique
Department of Pathology and Laboratory Medicine; Emory University; Atlanta, Georgia, USA.
Department of Pathology, Radboud University Medical Center, Nijmegen, The Netherlands.
Curr Opin Organ Transplant. 2025 Jun 1;30(3):201-207. doi: 10.1097/MOT.0000000000001213. Epub 2025 Apr 1.
The objective of this review is to provide an update on the application of artificial intelligence (AI) for the histological interpretation of kidney transplant biopsies.
AI, particularly convolutional neural networks (CNNs), has demonstrated great potential in accurately identifying kidney structures, detecting abnormalities, and diagnosing rejection with improved objectivity and reproducibility. Key advancements include the segmentation of kidney compartments for accurate assessment and the detection of inflammatory cells to aid in rejection classification. Development of decision support tools like the Banff Automation System and iBox for predicting long-term allograft failure have also been made possible through AI techniques. Challenges in AI implementation include the need for rigorous evaluation and validation studies, computational resource requirements and energy consumption concerns, and regulatory hurdles. Data protection regulations and Food and Drug Administration (FDA) approval represent such entry barriers. Future directions involve the integration of AI of histopathology with other modalities, such as clinical laboratory and molecular data. Development of more efficient CNN architectures could be possible through the exploration of self-supervised and graph neural network approaches.
The field is progressing towards an automated Banff Classification system, with potential for significant improvements in diagnostic processes and patient care.
本综述的目的是提供关于人工智能(AI)在肾移植活检组织学解释中的应用的最新情况。
人工智能,尤其是卷积神经网络(CNN),在准确识别肾脏结构、检测异常以及诊断排斥反应方面已展现出巨大潜力,具有更高的客观性和可重复性。关键进展包括对肾脏区域进行分割以进行准确评估,以及检测炎症细胞以辅助排斥反应分类。通过人工智能技术,还开发了如班夫自动化系统和iBox等决策支持工具来预测长期移植物功能衰竭。人工智能实施过程中的挑战包括需要进行严格的评估和验证研究、计算资源需求以及能源消耗问题,还有监管障碍。数据保护法规和美国食品药品监督管理局(FDA)的批准就是此类准入障碍。未来的发展方向包括将组织病理学人工智能与其他模式,如临床实验室和分子数据进行整合。通过探索自监督和图神经网络方法,有可能开发出更高效的CNN架构。
该领域正朝着自动化的班夫分类系统发展,有望在诊断过程和患者护理方面取得显著改善。